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Abstract The G protein L3 subunit (GNB3) 825T allele is
predictive of enhanced Gi protein activation. Studying the
influence of C825T allele status on cellular in vitro immune
responses towards recall antigens and interleukin-2 stimulation
we observed a 2^4-fold, significantly increased proliferation in
homozygous 825T (TT) vs. C825 allele (CC) carriers. Further-
more, lymphocyte chemotaxis and CD4+ T cell counts of
individuals with TT+TC genotypes were significantly enhanced
compared to the CC genotype. In summary, it appears that
C825T allele status is highly predictive of immunocompetence
and could be a candidate gene in disorders associated with
inadequate immune response. ß 2001 Federation of European
Biochemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
Heterotrimeric G proteins are important mediators of intra-
cellular signal transduction not only for heptahelical G pro-
tein-coupled receptors but also for some receptors with intrin-
sic tyrosine kinase activity. Initiating signals for G proteins
include the binding of hormones, chemokines, and neuro-
transmitters. Recently we described a C825T polymorphism
in the gene GNB3 encoding the L3 subunit of heterotrimeric G
proteins [1]. The 825T allele is associated with the generation
of a functionally active splice variant, GL3-s, which is ex-
pressed in cells from 825T allele carriers [1]. The 825T allele
is predictive of enhanced activation of pertussis toxin (PTX)-
sensitive G proteins as seen from enhanced chemotaxis of
human neutrophils towards N-formyl-methionyl-leucyl-phe-
nylalanine or interleukin (IL)-8 [2,3]. Transient expression of
GL3-s in COS-7 cells enhances chemotaxis which underscores
the functional importance of this splice variant in enhancing
G protein activation [3]. As there were hints for an in£uence
of GNB3 genotype on innate cellular immunity (chemotaxis of
neutrophils), we speculated that regulation of the speci¢c cel-
lular immune response may also be a¡ected by GNB3 geno-
types.
To investigate if GNB3 genotype modulates speci¢c cellular
immune response, lymphocyte transformation after stimula-
tion with common recall antigens, and IL-2 as well as lym-
phocyte chemotaxis and also lymphocyte subpopulations were
analyzed.
2. Materials and methods
2.1. Study subjects
Venous blood samples were obtained from healthy, male, non-
smoking individuals selected for TT, TC, and CC genotypes (n = 63
for lymphocyte transformation tests (LTT), n = 35 for IL-2-induced
proliferation, n = 23 for PTX inhibition assays, n = 10^30 for chemo-
taxis assays (depending on the experimental setting), and n = 202 for
enumeration of leukocytes by £ow cytometry). Besides, non-selected
healthy medical sta¡ and students (27 female, 25 male) were booster-
vaccinated against hepatitis B virus (HBV, Gen H-B-Vax, Chiron
Behring, Marburg, Germany) on average 1.5 years after their last
immunization and heparinized blood was taken 1 week after booster
shot to perform an HBV-speci¢c LTT.
2.2. DNA genotyping
Genomic DNA was extracted from EDTA-blood with a proprietary
reagent (Qiagen, Hilden, Germany) according to the manufacturer’s
protocol. GNB3 C825T allele status was determined after PCR am-
pli¢cation and restriction analysis as described [1].
2.3. Lymphocyte proliferation in response to recall antigens, mitogens,
and IL-2
Cellular in vitro responses towards 12 recall antigens (six di¡erent
concentrations each) and the mitogens phytohemagglutinin (PHA,
0.5^4 Wg/ml), concanavalin A, (5^40 Wg/ml), pokeweed mitogen
(0.6^5 Wg/ml), and anti-CD3 (OKT3, 0.03^0.25 Wg/ml) were quanti¢ed
using standardized assay formats (LT2 antigen, No. 7051, BAG, Lich,
Germany, LTT mitogen: in-house prepared) as described previously
[4]. In a separate assay, cells were stimulated with IL-2 (25 and 100
U/ml, Proleukin, Chiron, Ratingen, Germany). In brief, peripheral
blood mononuclear cells (PBMCs) from heparinized blood were col-
lected after Ficoll-Paque1 density gradient (Amersham Pharmacia
Biotech, Uppsala, Sweden) centrifugation and 50 000 cells were incu-
bated with antigens, mitogens, and IL-2, respectively, in 200 Wl of cell
culture medium (RPMI 1640, Gibco, Life Technologies, Paisley, UK,
with 10% of inactivated pooled human serum, Institute of Transfusion
Medicine, University Hospital, Essen, Germany) per well of microtiter
plates (37‡C, 5% CO2). Mitogen cultures were set up as quadrupli-
cates for 3 days. Antigen and IL-2 cultures were grown in sixtuplicates
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for 5 days and triplicates for 6 days, respectively. For the last 16 h, the
cultures were labeled with 1 WCi [3H]thymidine per well (TRA.120,
speci¢c activity 5 Ci/mmol, Amersham, Buckinghamshire, UK). The
cultures were then harvested (Micro96 Harvester, Skatron Instru-
ments, Transby, Norway) onto glass ¢ber ¢ltermates (Wallac, Turku,
Finland) and the incorporated radioactivity was quanti¢ed by liquid
scintillation counting (1205 Betaplate, Wallac). For evaluation, the
second highest [3H]thymidine uptake of antigen and IL-2 cultures
was chosen. In addition, each antigen concentration was considered
separately. Increment counts per minute (cpm) values were generated
as antigen and IL-2 proliferation minus autologous (unstimulated)
proliferation. In some experiments, PBMCs (5U106/ml) were pre-in-
cubated with or without PTX (100 ng/ml) for 24 h in RPMI 1640 plus
10% pooled inactivated human serum. Thereafter, determination of
lymphocyte proliferation in response to recall antigens, and IL-2 was
performed as described above.
Furthermore, cellular immune response towards a puri¢ed protein
of the PreS1-S2-S region of HBV (0.25^1.0 Wg/ml, adw subtype,
kindly provided by Dr. K.-H. Heermann, Go«ttingen, Germany) was
determined in 52 booster vaccinated probands. In contrast to stand-
ardized LTT against 12 recall antigens, this assay used 200 000
PBMCs per culture.
2.4. Chemotaxis assay
PBMCs were resuspended in RPMI 1640 plus 1% fatty acid-free
bovine serum albumin (BSA) (Sigma, Deisenhofen, Germany) and
transferred to cell culture dishes. After 30 min the non-adherent cells
were collected, centrifuged and resuspended in RPMI 1640 plus 1%
fatty acid-free BSA. All cell preparations consisted of at least 95%
mononuclear cells, as determined by staining with Di¡-Quick0 (Dade
Behring AG, Marburg, Germany), and the fraction of CD3 T lym-
phocytes was determined to be s 90% by £ow cytometry (CD3 mono-
clonal antibody (mAb), Becton Dickinson, Heidelberg, Germany).
Peripheral blood lymphocytes (PBLs) were resuspended in RPMI
1640 plus 10% heat-inactivated fetal calf serum, 1 Wg/ml PHA and
100 U/ml IL-2 for activation and left in a humidi¢ed atmosphere with
5% CO2 at 37‡C for 72 h. CD4 and CD8 T lymphocytes were
prepared by negative selection with Cellect1 cell enrichment immu-
nocolumns (Cytovax Biotechnologies, Edmonton, Canada). In some
experiments the cells were pretreated for 24 h with 100 ng/ml PTX.
Chemotaxis of PBLs and subsets of T lymphocytes was determined in
a 48-well microchemotaxis chamber as described [2] with minor mod-
i¢cations: stromal cell-derived factor 1K (SDF-1K, Peprotech, Rocky
Hill, USA) was diluted in RPMI 1640 with 0.1% fatty acid-free BSA.
The PBL suspension was adjusted to a density of 2U106 cells/ml
RPMI 1640 with 1% fatty acid-free BSA. 50 Wl of the cell suspension
was applied to the upper wells of the microchemotaxis chamber sep-
arated from the lower wells by a polyvinylpyrrolidone-free polycar-
bonate ¢lter membrane with a pore size of 5 Wm coated overnight with
6.7 Wg/ml ¢bronectin (Sigma). Migration of PBLs was allowed for 2 h
in a humidi¢ed atmosphere with 5% CO2 at 37‡C. Migrated cells were
quanti¢ed on the lower side of the ¢lter after staining with Di¡-
Quick0 by counting cells in three random areas of each well under
a microscope with a magni¢cation of 400-fold (high power ¢eld, HPF)
and calculating the mean per HPF.
2.5. Flow cytometric analysis
Three-part di¡erentiation of PBMCs was performed with lysed
whole-blood by £ow cytometry (Calibur, Becton Dickinson, Heidel-
berg, Germany) using CD14 and CD45 mAb. Lymphocyte subsets
were identi¢ed with the mAb combinations: CD3/CD4/CD8, CD3/
CD19, CD3/CD25, CD4/CD49d (integrin VLA4), CD4/CD62L (L-se-
lectin), and CD3/HLA-DR. Analysis of CD4 or HLA-DR T cells
was conducted additionally using a linear format to measure channel
£uorescence intensities as numerals and to calculate mean £uorescence
intensity (MFI) values [5].
2.6. Statistical analysis
Unpaired, two-tailed Student’s t-test was used to compare lympho-
cyte proliferation in response to recall antigens and IL-2 as well as
chemotaxis between the TT, TC, and CC genotype groups. Cell
counts were compared using two-tailed Kruskal^Wallis or Wilcoxon
tests. Di¡erences were regarded statistically signi¢cant at P6 0.05.
3. Results
3.1. Enhanced in vitro response of lymphocytes from 825T
allele carriers to recall antigens and IL-2, but not to
mitogens
The proliferative response of PBMCs obtained from indi-
viduals with TT (n = 14), TC (n = 22), and CC (n = 27) geno-
types following stimulation with four common recall antigen
is summarized in Fig. 1A^D. We observed a 2^4-fold in-
creased proliferation of T cells from individuals homozygous
for the 825T allele compared to homozygous C825 allele car-
riers. This increase reached statistical signi¢cance (P6 0.05)
for the following antigens tested: tuberculin (PPD):
66 240 þ 11 160 vs. 27 220 þ 5029, tetanus: 86 670 þ 17 870 vs.
38 610 þ 7545, Candida albicans : 45 190 þ 7667 vs. 26 290 þ
3809, cytomegalovirus: 13 480 þ 4444 vs. 5291 þ 1672, herpes
simplex virus (HSV)-type 1: 32 750 þ 8561 vs. 11 160 þ 2467,
Mumps: 11 070 þ 3568 vs. 2975 þ 514, in£uenza-A: 14 430 þ
5118 vs. 6397 þ 1022, and in£uenza-B: 14 380 þ 4636 vs.
3936 þ 759 (all values are means of cpm increment of the
second highest value þ standard error of the mean (S.E.M.)).
Responses towards antigens like diphtheria, rubella, Varicella
zoster virus, and measles showed a similar tendency which just
escaped statistical signi¢cance (data not shown). In addition,
antigen-induced cell proliferation was enhanced in individuals
with TT vs. TC genotype and reached statistical signi¢cance
for PPD and HSV-type 1 (P6 0.05). Furthermore, the prolif-
erative response to IL-2 (25 and 100 U/ml) was also signi¢-
cantly (P6 0.05) increased in cells of homozygous T allele vs.
homozygous C allele blood donors (Fig. 1E). After IL-2 stim-
ulation (25 U/ml) increments were 85 090 þ 21 840 cpm (n = 9),
61 680 þ 17 450 cpm (n = 10), and 36 990 þ 7119 cpm (n = 16) of
individuals with TT, TC, and CC genotypes, respectively. The
above results persisted after correction for increased CD4
cell counts in 825T allele carriers. In contrast, after stimula-
tion with mitogens the proliferative response of PBMCs was
not signi¢cantly di¡erent between genotypes. Mean cpm and
S.E.M. values for TT vs. CC allele carriers were 198 200 þ
17 430 vs. 225 400 þ 12 600 (PHA), 133 300 þ 10 880 vs.
161 800 þ 7452 (concanavalin A), 59 630 þ 8869 vs. 60 880 þ
5737 (pokeweed mitogen), and 102 100 þ 15 420 vs. 100 500 þ
9991 (OKT3).
Antigen- and IL-2-induced proliferations were actually de-
pendent on activation of PTX-sensitive Gi proteins as con-
¢rmed by experiments in which lymphocytes of 23 individuals
were pretreated with 100 ng/ml PTX for 24 h prior to stim-
ulation. T lymphocyte proliferation against recall antigens was
signi¢cantly (P6 0.05) reduced to 28 þ 14% (range for the
di¡erent antigens 8^66%), against mitogens to and against
IL-2 to 58 þ 8% of controls. This inhibition by PTX was in-
dependent of C825T allele status (data not shown).
Expanding the data to a more representative group of 52
booster-vaccinated probands (TT: n = 4, TC: n = 20, CC:
n = 28) cellular in vitro responses against PreS1-S2-S HBV
antigen showed a signi¢cant (P6 0.05) 2.5-fold increase in
PBMCs from individuals carrying the 825T allele compared
to those homozygous for the C825 allele (Table 1). In this
setting TT and TC carriers were analyzed together because
of the small size of the TT group; the cpm increment values
were 31 230 þ 25 620 (TT) and 32 460 þ 6836 (TC).
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3.2. Enhanced chemotactic response of lymphocytes
Stimulation of non-activated PBLs with SDF-1K, a chemo-
kine which activates T cells via the G protein-coupled CXCR4
receptor [6,7], induced chemotaxis at concentrations above 10
ng/ml with maximum e⁄cacy at 1000 ng/ml (Fig. 2A). The
chemotactic response of lymphocytes from 825T allele carriers
was signi¢cantly enhanced (P6 0.05) compared to that from
homozygous C825 allele carriers (Fig. 2A). After activation of
cells for 72 h with PHA and IL-2 this e¡ect was even more
pronounced (Fig. 2B). The e⁄cacy and potency of SDF-1K to
induce migration of lymphocytes were increased with an opti-
mum at 300 ng/ml. Signi¢cantly enhanced chemotaxis of lym-
phocytes from homo- or heterozygous 825T allele carriers was
observed at 10^300 ng/ml SDF-1K. Enrichment of CD4 and
CD8 T cells by negative selection suggested that the en-
hanced response is apparently restricted to CD4 T lympho-
cytes (Fig. 2C). The total number of migrated cells was sig-
ni¢cantly di¡erent at 1000 ng/ml SDF-1K : 247.8 þ 44.1
(TT+TC genotype) vs. 88.7 þ 13.9 cells per HPF. In contrast,
SDF-1K-stimulated chemotaxis of CD8 T lymphocytes was
independent of C825T allele status. PTX completely abolished
the SDF-1K-induced chemotaxis of all T lymphocytes indicat-
ing the involvement of Gi proteins in CXCR4 signaling (data
not shown).
3.3. Di¡erences in leukocyte subsets
825T allele (TT+TC) carriers had signi¢cantly higher
CD3CD4 counts (n = 100, mean þ S.E.M.: 43.4 þ 0.7%,
778 þ 26 cells/Wl) than homozygous C825 allele carriers
(n = 102, 40.7 þ 0.7%, 694 þ 20 cells/Wl). However, there was
no di¡erence between individuals homo- and heterozygous
for the T allele (TT: n = 17, 42.6 þ 1.9%, 761 þ 55 cells/Wl ;
TC: n = 83, 43.6 þ 0.7%, 782 þ 29 cells/Wl). In contrast, we
could not detect signi¢cant di¡erences for CD3CD8,
CD19, or CD14 cell counts between genotypes. Markers
of cell activation and adhesion such as CD25 and HLA-DR
on T cells, and CD49d (integrin VLA4) and CD62L (L-selec-
tin) on CD4 T cells did not di¡er between carriers and non-
carriers of the 825T allele (TT+TC: n = 20, CC: n = 10). Mea-
suring MFI of CD4 and HLA-DR expression on T cells did
also not yield any di¡erence (TT+TC: n = 20, CC: n = 10).
Table 1
Cellular in vitro response towards HBV antigen after HBV booster
GNB3 genotype Increment (cpm)
TT+TC (n = 24) 32 250 þ 6 815a
CC (n = 28) 13 030 þ 5 347
Total (n = 52) 21 900 þ 4 429
LTT towards puri¢ed PreS1-S2-S HBV antigen in 825T allele car-
riers showed a 2.5-fold increase in cell proliferation using 2U105
PBMCs. Data are given as mean þ S.E.M.
aP6 0.05 for TT+TC vs. CC genotypes.
Fig. 1. TT, TC, and CC GNB3 genotypes and T cell responses.
LTT towards common recall antigens (A^D) and IL-2 (E) showed
2^4-fold increases in cell proliferation comparing TT and CC pro-
bands. Data are presented for PPD, tetanus, C. albicans, and HSV-
type 1, the most widely distributed antigens tested. Data are given
as mean þ S.E.M. Unpaired Student’s t-tests were performed sepa-
rately for each antigen/IL-2 concentration. *P6 0.05, **P6 0.01,
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4. Discussion
The GNB3 polymorphism clearly de¢nes di¡erent levels of
T lymphocyte response capacity as proliferation was signi¢-
cantly elevated in TT vs. CC allele carriers after stimulation
with common recall antigens. The in vitro antigen stimulation
mimics the in vivo situation of a second or repeated contact
with a speci¢c antigen. Speci¢c cellular recognition of the
antigens tested in vitro could be either caused by preceding
infections, e.g. with C. albicans or by vaccinations, e.g. against
tetanus, diphtheria, or HBV. As could be demonstrated in
booster vaccinated probands cellular immune response follow-
ing a repeated in vivo contact with an HBV antigen resulted
in a more vigorous in vitro response in individuals carrying
the 825T allele. Therefore, one may assume that vaccinations
in 825T allele carriers could be more e¡ective, i.e. less doses of
vaccine or longer intervals between vaccinations may be fea-
sible to achieve comparable cellular responses. In addition, it
could be postulated that 825T allele carriers may better defeat
infectious diseases in which cellular activation involving T
cells is essential. The impact of GNB3 genotypes on infectious
and in£ammatory diseases has been mentioned in kidney al-
lograft recipients [8]. It was described that these diseases when
leading to death were signi¢cantly less frequent in recipients
with 825T graft.
Apart from GNB3 also the polymorphic HLA system con-
trols cellular and humoral immune responses [9,10]. HLA
molecules are required for antigen-derived peptide presenta-
tion and activation of T lymphocytes and play a central role
in the speci¢c immune response. Especially after HBV-speci¢c
vaccination an e¡ect of certain HLA class II alleles on the rate
of good or poor antibody response was described [10]. In
terms of immune response an interaction between HLA and
GNB3 genes located on chromosomes 6p and 12p, respec-
tively, should not be expected.
PTX inhibition experiments con¢rmed that Gi proteins are
involved in T cell signal transduction following stimulation
with recall antigens and IL-2 [11]. Data on T cells and the
involvement of a G protein in the antigen, and cytokine-in-
duced responses are still controversial. Some evidence indi-
cated that a G protein couples the T cell receptor to phos-
pholipase C [12]. But direct evidence is lacking supporting the
involvement of a G protein in T cell receptor-mediated acti-
vation of phospholipase C-Q1 [13]. Other authors refused the
idea of this direct coupling [14]. In contrast, Gi protein in-
volvement in the antigen receptor-mediated signal transduc-
tion has been clearly shown for B lymphocytes [15]. It was
described that a PTX-sensitive G protein regulates tyrosine
phosphorylation of phospholipase C-Q1 by controlling the ac-
tivity of a protein tyrosine kinase. Following these data, one
can assume that T cells of GNB3 825T carriers display an
enhanced G protein activation after stimulation with recall
antigens and IL-2 (but not with mitogens), resulting e.g. in
a longer or more e¡ective activation of phospholipase C or an
intermediate molecule via GL3-s.
Besides, the chemotactic response of T lymphocytes, espe-
cially CD4 T cells from 825T allele carriers, was signi¢cantly
enhanced compared to homozygous C825 allele carriers.
These ¢ndings are unlikely fortuitous for several reasons: (i)
chemotaxis is known to be regulated via GLQ subunits re-
leased from PTX-sensitive G proteins [16,17], (ii) increased
chemotaxis was recently found enhanced in neutrophils from
Fig. 2. GNB3 genotypes and T cell chemotaxis. (A) Migration of
PBLs was stimulated with the indicated concentrations of SDF-1K
for 2 h in a 48-well microchemotaxis chamber. Open circles, CC
genotype (n = 14); ¢lled circles, TC (n = 11) and TT (n = 5) geno-
types. (B) Chemotactic response of PHA/IL-2-activated PBLs in re-
sponse to the indicated concentrations of SDF-1K : open circles, CC
genotype (n = 11); ¢lled circles, TC (n = 10) and TT (n = 1) geno-
types. (C) Chemotaxis of negatively selected CD4 or CD8 in re-
sponse to stimulation with 1000 ng/ml SDF-1K : open bars, CC geno-
type (n = 5); ¢lled bars, TC (n = 4) and TT (n = 1) genotypes. Data
represent the mean þ S.E.M. of migrated cells per HPF. *P6 0.05
and **P6 0.01 for the di¡erence between TT+TC vs. CC geno-
types.
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GNB3 825T allele carriers [2], and (iii) the transfection of the
splice variant GL3-s associated with the 825T allele into COS-
7 cells causes enhanced neutrophil chemotaxis [3]. In contrast
to antigen-speci¢c cell proliferation, heterozygosity for the
825T allele was su⁄cient for this e¡ect and no further en-
hancement was observed in cells from homozygous 825T allele
carriers. As the GNB3 C825T allele status obviously in£uences
chemotaxis, antigen-speci¢c cellular immune response as well
as IL-2-induced proliferation, there seems to exist one com-
mon central step of signal transduction in CD4 T cells that
may be facilitated in cells expressing GL3-s associated with the
825T allele.
CD4 counts were signi¢cantly elevated in TT+TC vs. CC
carriers. As CD4 cells are essential for speci¢c cellular im-
mune response, their increased numerical presence should re-
sult in an enhanced immune function. In contrast to CD4
the CD8 cell counts were not in£uenced by the GNB3 poly-
morphism. Very recently it was shown that the G protein-
coupled receptors GPK2 and Edg-4 are di¡erently expressed
on CD4 cells compared to CD8 cells [18,19]. It is therefore
conceivable that predominantly CD4 T cells are in£uenced
by the G protein polymorphism GNB3. Few data are avail-
able on the regulation of CD4 cell counts in humans: family
analysis showed a genetic control of the CD4/CD8 T cell ratio
in humans through yet unde¢ned genes [20]. This ratio also
appears to be in£uenced by race and environmental factors
[21,22]. The expression of the CD4 gene is controlled by at
least ¢ve distinct transcription control elements, including the
promoter, three enhancers, and a silencer designated HES
(hairy/enhancer of split homologue)-1 [23]. The exact mecha-
nisms underlying increased CD4 cell counts in 825T allele
carriers remain to be de¢ned. We have no evidence for an
increased production of CD4 cells and, thereby, total mass
of CD4 cells. Increased chemotactic response to certain cy-
tokines could be one decisive factor. On the other hand, in-
creased counts of CD4 cells in 825T allele carriers could
result from an altered distribution of CD4 cells between
lymphatic organs and peripheral blood. In mice, thymocyte
emigration and migration of B and T lymphocytes into splenic
white pulp cords is PTX-sensitive and, thus, involves Gi pro-
teins [24,25]. Another possible mechanism explaining higher
CD4 counts in 825T allele carriers could be a decrease in
apoptosis ^ this has to be further analyzed.
Our results described above may help to understand and to
predict individual cellular immune reactions, e.g. in the cause
of HIV-1 or microbial infections, allotransplantation, or auto-
immune phenomena. As could be shown recently, kidney al-
lograft survival is decreased in grafts from donors homozy-
gous for the 825T allele [8]. Perpetuated arteriolar media
hypertrophy which leads to progressive allograft injury was
supposed as mechanism occurring more frequent in homozy-
gous 825T allele carriers. It is likely that other immune func-
tions and disorders are as well in£uenced by C825T allele
status. The data presented here may help to elucidate the
extent and contribution of altered cellular immune functions
in homo- and heterozygous 825T allele carriers associated
with di¡erent disease outcomes.
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